Question 1

Is Ozempic FDA-approved for weight loss?

Accepted Answer

No. Ozempic is FDA-approved only for type 2 diabetes (December 2017). Semaglutide is approved for chronic weight management under the brand name Wegovy at a higher 2.4 mg weekly dose. Any Ozempic prescription written for weight loss alone is off-label.

Question 2

Why does Qsymia have a REMS program?

Accepted Answer

Topiramate is teratogenic and has been linked to oral cleft birth defects when used in the first trimester. The FDA-required Risk Evaluation and Mitigation Strategy (REMS) mandates that prescribers and patients confirm effective contraception and that women of reproductive potential undergo monthly pregnancy testing while on Qsymia.

Question 3

Which produces more weight loss in trials?

Accepted Answer

Direct head-to-head trials do not exist. Qsymia at the top 15/92 mg dose produced -10.9% total body weight loss at 56 weeks in EQUIP (Allison 2012, PMID 22051941). Ozempic itself has not been studied for weight loss at this brand, but the same molecule (semaglutide) at the higher 2.4 mg Wegovy dose produced ~-14.9% in STEP-1. Off-label Ozempic at 1-2 mg typically produces ~10-15%.

Question 4

Which is cheaper out of pocket?

Accepted Answer

Qsymia is dramatically cheaper. Brand Qsymia through the Qsymia Advantage program runs about $100-$200 per month, and the unbundled generic combination (separate phentermine + topiramate) can be filled for roughly $50/month. Ozempic cash pricing through NovoCare is $599-$899 per month without insurance.

Question 5

Can I switch from Ozempic to Qsymia?

Accepted Answer

Yes, with prescriber supervision. There is no pharmacologic interaction between a discontinued GLP-1 and starting Qsymia, but patients should taper any antiemetic regimen, confirm they are not pregnant, enroll in the Qsymia REMS contraception attestation, and monitor blood pressure since phentermine is sympathomimetic. Patients with uncontrolled hypertension, hyperthyroidism, glaucoma, or MAOI use should not take Qsymia.

Question 6

Is Qsymia safe long-term?

Accepted Answer

Qsymia was FDA-approved in July 2012 based on 56-week trial data (EQUIP, CONQUER) and a 108-week safety extension (SEQUEL). Long-term concerns include modest increases in heart rate, paresthesia, cognitive complaints (memory, attention, word-finding), kidney stones, and metabolic acidosis from the topiramate component. There is no cardiovascular outcomes trial comparable to SUSTAIN-6 for semaglutide.

Field	Ozempic	Qsymia
FDA Indication	Type 2 diabetes only (weight loss is off-label)	Chronic weight management (BMI 30+, or 27+ with comorbidity)
Mechanism	GLP-1 receptor agonist (incretin mimetic)	Sympathomimetic amine + GABA modulator/carbonic anhydrase inhibitor
Route & Frequency	Subcutaneous injection, once weekly	Oral capsule, once daily (morning)
Average Weight Loss (56 wk)	~10-15% off-label (extrapolated from SUSTAIN/STEP semaglutide data)	-10.9% (EQUIP, top dose 15/92 mg)
Pivotal Trial Result	Not studied for weight loss at this brand/dose; Wegovy STEP-1 -14.9%	-9.8% placebo-subtracted at 56 wk (CONQUER)
Cash Price (US, monthly)	$599-$899 (NovoCare direct)	$100-$200 brand; ~$50 generic phentermine-topiramate
Pregnancy Safety / REMS	Not recommended in pregnancy; no REMS program	REMS required: teratogenic (cleft lip/palate); contraception + monthly pregnancy testing mandated
Common Side Effects	Nausea, vomiting, diarrhea, constipation	Paresthesia, dry mouth, dysgeusia, insomnia, cognitive slowing

Ozempic vs Qsymia: GLP-1 Off-Label vs FDA Anti-Obesity Pill

The verdict

Side-by-side comparison

Frequently asked questions